Skip to main content

Gynecologic Cancer Steering Committee

The Gynecologic Cancer Steering Committee (GCSC), one of 10 disease-specific steering committees focuses on studies in major gynecologic cancers of ovarian, uterine, and cervicovaginal origin. In its monthly meetings, the GCSC addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in adult gynecologic cancers. The GCSC also recognizes its role in fostering collaboration with groups and institutions engaged in conducting trials in gynecologic cancers. View the GCSC member roster.

Strategic Priorities

  • GCSC Strategic Priorities were formulated with the goal that the majority of submitted concepts would align with these established priorities. They address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment.

Task Forces

  • Task forces were established to  discuss concepts and make recommendations for clinical trial planning meetings in their disease subtypes:
    • cervical cancer
    • ovarian cancer
    • uterine cancer

Clinical Trial Planning Meetings (CTPMs)

CTPMs are held periodically and focus on specific clinical trial-related topics. The following are important GCSC CTPMs:

  • Defining and Targeting Molecular Pathways to Direct Personalized Value-added Treatments for Patients with Epithelial Ovarian Cancer  
    In February 2021, the GCSC convened a CTPM to identify and prioritize novel and existing therapeutics and combinations to target scientifically defined ovarian cancer subgroups in an effort to advance precision therapy of epithelial ovarian cancer. Read the executive summary.
  • Moving Forward in Cervical Cancer - Enhancing Susceptibility to DNA Repair Inhibition and Damage  
    In October 2018, a CTPM was convened with a goal to comprehensively review the biologic understanding of HPV-related cervical cancer, its susceptibility to DNA damage repair modulation, and identification of potential drivers, such as ribonucleotide reductase to maximize new therapeutic strategies for the treatment of advanced or metastatic cervical cancer. The meeting focus was the integration of biology with precision-based therapies to build new directions for treatment of cervical cancer. Read the executive summary and full publication in JNCI.
  • Designing Targeted Trials for Targeted Endometrial Cancer Populations Using Targeted Agents
    Despite a 50 percent increase in endometrial cancer incidence, with a nearly 300 percent increase in deaths over the period from 1987 to 2008, no new agents have been approved for treatment of endometrial cancer over this same two-decade period. In January 2016, a CTPM was convened with the goal of integration of molecular and/or histologic stratification into endometrial cancer management. Read the executive summary and full publication in Oncotarget, Gynecol Oncol
  • Ovarian Cancer CTPM
    In October 2011, the GCSC convened a clinical trial planning meeting to identify key tumor types, associated molecular pathways, and biomarkers for targeted drug intervention. A more integrated and efficient approach for screening new agents using smaller selective randomized trials in specific disease-type settings was endorsed, together with collaborative funding models between industry and the national clinical trials network. Read the executive summary and JNCI commentary summary.
  • Cervical Cancer CTPM
    In September 2007, GCSC sponsored a meeting to review current knowledge focused on pretreatment evaluation and prognostic markers in cervical cancer and make recommendations for future research. Read about the proceedings and conclusions of that meeting in the Gynecologic Oncology Meeting Report.
  • Endometrial Cancer State of the Science
    In November 2006, GCSC sponsored a meeting for our understanding of endometrial cancer (EC) and uterine carcinosarcoma and to develop new treatment strategies to improve outcomes. Read the meeting summary and the full publication article.


For more information, contact Wolf Lindwasser, Ph.D., at